Dr. Anca D. Askanase, MD

Dr. Askanase practices at Hospital for Special Surgery in New York, New York, part of Hospital for Special Surgery.

Dr. Askanase's NPI, 1558336768, was assigned on February 21, 2006. Dr. Askanase graduated from Carol Davila University of Medicine and Pharmacy in 1989. Dr. Askanase holds New York license 215150-1.

Dr. Askanase's primary practice is Hospital for Special Surgery, at 535 East 70th Street, New York, NY 10021 in New York County. The practice phone is (212) 606-1000.

Dr. Askanase's primary practice is Hospital for Special Surgery in New York, New York, part of Hospital for Special Surgery. Dr. Askanase is also affiliated with NewYork-Presbyterian/Weill Cornell Medical Center. The medical group on file is ColumbiaDoctors. Dmand AI also links Dr. Askanase to 2 more medical groups and 1 group practice or clinic, each named with a free account. Dr. Askanase's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Askanase practices, 3 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Askanase's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Askanase is board certified in rheumatology by the American Board of Internal Medicine. Dr. Askanase is licensed in New York.

Dmand AI lists arteritis, arthritis, gout, joint pain, lupus, muscle pain, fibromyalgia, and limb pain, osteoporosis and rheumatoid arthritis among the conditions Dr. Askanase treats.

CMS data shows 317 Medicare services from Dr. Askanase across 3 procedure codes in 2024, for 94 Medicare patients. Medicare paid $30,386 for them. Every service was in an office.

CMS counts 94 Medicare patients who saw Dr. Askanase in 2024. The largest group is 65 to 74, with 35 patients. 67% of them have arthritis, and 66% have high cholesterol. 26% are also on Medicaid. Their average risk score is 1.84, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Askanase's median patient age at 51, with 81% women.

In 2024, Dr. Askanase wrote 359 Medicare Part D claims for 75 patients. 89% of them were for generic drugs. CMS names the drug for 164 of them, across 8 drugs with 11 or more claims each, at $61,939 in total drug cost. In 2023, CMS named 185 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Askanase for performance year 2024, reported through an alternative payment model (APM). Dr. Askanase accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Askanase as offering telehealth.

Dmand AI links 180 papers to Dr. Askanase, published from 2009 to 2025. 2020 was the busiest year, with 20. The most frequent topics are Lupus Erythematosus, Systemic, Immunosuppressive Agents and Glucocorticoids. Dr. Askanase has published most often in Lupus Sci Med. Dr. Askanase's most frequent co-authors are Kenneth Carekin Kalunian, MD, Daniel J. Wallace, MD and Cynthia B. Aranow, MD.

Dmand AI links Dr. Askanase to 4 clinical trials. Conditions studied include Coronaviridae Infections, Leukemia, Myeloid, Acute and Lupus Erythematosus, Systemic. Columbia University sponsors the most, 2. Open Payments lists research payments to Dr. Askanase that name 2 trials.

CMS Open Payments shows 158 general payments to Dr. Askanase from 23 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 77% of the total. AstraZeneca Pharmaceuticals LP paid the most, $43,779. It also lists 21 research payments totaling $27,169 from 2017 to 2024, naming 2 clinical trials.

Dmand AI lists 1 award for Dr. Askanase, most recently CMS Stage 1 EHR in 2013.

Dr. Askanase graduated from Carol Davila University of Medicine and Pharmacy in 1989.

Dr. Askanase is in network with 16 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.